SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 7,378,508 entitled “Polymorphic Crystalline Forms Of Tiacumicin B.” This patent includes claims covering a novel polymorphic form of the active pharmaceutical ingredient in the investigational drug candidate, OPT-80. The patent specifically claims the Form A polymorph of OPT-80, as well as all dosage forms and pharmaceutical compositions including the Form A polymorph of OPT-80. OPT-80 is currently in two Phase 3 clinical trials for the treatment of Clostridium difficile infection, or CDI, also known as C. difficile-associated disease, or CDAD.
